Stay updated with breaking news from Mutant Lung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Jul 27, 2023--
Data support ongoing discussions with global health authorities ...
The treatment combination of Rybrevant and chemotherapy significantly improved progression-free survival rates for patients newly diagnosed with metastatic NSCLC with EGFR Exon 20 insertion mutations.
AstraZeneca and Daiichi Sankyo’s ENHERTU showed an objective response rate of 37.1% in the overall population of the DESTINY-PanTumor02 Phase II trial ENHERTU is the first therapy to show... | June 5, 2023
The phase 3 HARMONi trial recently kicked off, studying ivonescimab plus chemotherapy for EGFR-mutant non-small cell lung cancer.